KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash & Equivalents: 2017-2024

Historic Cash & Equivalents for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $71.5 million.

  • Aquestive Therapeutics' Cash & Equivalents rose 65.69% to $129.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.1 million, marking a year-over-year increase of 65.69%. This contributed to the annual value of $71.5 million for FY2024, which is 199.71% up from last year.
  • According to the latest figures from FY2024, Aquestive Therapeutics' Cash & Equivalents is $71.5 million, which was up 199.71% from $23.9 million recorded in FY2023.
  • Aquestive Therapeutics' 5-year Cash & Equivalents high stood at $71.5 million for FY2024, and its period low was $23.9 million during FY2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $27.3 million (2022), whereas its average is $40.9 million.
  • Per our database at Business Quant, Aquestive Therapeutics' Cash & Equivalents plummeted by 35.52% in 2020 and then skyrocketed by 199.71% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Cash & Equivalents (Yearly) stood at $31.8 million in 2020, then declined by 11.89% to $28.0 million in 2021, then decreased by 2.68% to $27.3 million in 2022, then decreased by 12.47% to $23.9 million in 2023, then spiked by 199.71% to $71.5 million in 2024.